Incyte Corporation: Neoplasms trials

The registry lists 22 Neoplasms studies with Incyte Corporation as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 20Phase 2 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.TerminatedNCT04949191Phase 2Results posted
• Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)TerminatedNCT04003623Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsTerminatedNCT03361228Phase 1/2Results posted
• A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedNCT03347123Phase 1/2Results posted
• INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedNCT03277352Phase 1/2Results posted
• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2Results posted
• A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)CompletedNCT03085914Phase 1/2Results posted
• Study of INCB053914 in Subjects With Advanced MalignanciesTerminatedNCT02587598Phase 1/2Results posted
• An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesTerminatedNCT02431260Phase 1/2Results posted
• An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedNCT02265510Phase 1/2Results posted
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedNCT02018861Phase 1/2Results posted
• Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedNCT04989387Phase 1
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.CompletedNCT04831944Phase 1
• A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid TumorsCompletedNCT03910530Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedNCT03589651Phase 1
• A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)CompletedNCT03235570Phase 1
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
• Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedNCT02559492Phase 1
• A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2
• A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedNCT01195311Phase 1
• A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedNCT01072266Phase 1